 After facing rebuke from FDA, CytoDyn Inc OTC: CYDY plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix leronlimab-PRO 140 for severe to critically ill COVID-19 patients to regulatory agencies, including those in India and the Philippines. Patients in the CD12 trial were administered two doses of leronlimab; on day zero and day seven. 